Abbott Concludes Vysis Acquisition | GenomeWeb

NEW YORK, Nov. 30—Abbott Laboratories concluded its acquisition of Vysis as scheduled at midnight on November 29.

The pharmaceutical company commenced a cash tender offer on Oct. 31 to purchase all outstanding shares of the genomics-based disease management company. 

As a final step, remaining Vysis shareholders will receive the same $30.50 per share cash price as paid in the tender offer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.